Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting
Zanidatamab preclinical data reveals additional differentiated mechanisms of action including unique ability to induce complement dependent cytotoxicity ProTECT™ (PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting), the first conditionally-active antibody technology that simultaneously addresses both ends of the therapeutic window Preclinical IL-12 and 4-1BB programs represent future therapeutic opportunities VANCOUVER, British Columbia — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced five presentations at the American Association for Cancer Research (AACR) Annual Meeting. The presentations highlight preclinical data that reveal new insights into the unique mechanisms of action of lead clinical candidate, zanidatamab, introduce Zymeworks’ fourth therapeutic platform, ProTECT™, and describe two new preclinical assets focused on the cytokine, IL-12, and the immune-oncology target, 4-1BB.